Commentary: Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis

Boning Zeng1,2†, Rui Xing3†, Changjiang Dong4 and Feiyue Xing1,2*

1 Department of Immunobiology, Institute of Tissue Transplantation and Immunology, Jinan University, Guangzhou, China, 2 MOE Key Laboratory of Tumor Molecular Biology, Key Laboratory of Functional Protein Research of Guangdong, Higher Education Institutes, Jinan University, Guangzhou, China, 3 MOE Key Laboratory of Protein Sciences, Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China, 4 BioMedical Research Center, University of East Anglia, Norwich, United Kingdom

*Correspondence: Feiyue Xing tfyxing@jnu.edu.cn
† These authors have contributed equally to this work

Keywords: group 3 innate lymphoid cell, pulmonary tuberculosis, mycobacterium tuberculosis, CXCR5, CXCL13, iBALT

A Commentary on Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis

by Ardain, A., Domingo-Gonzalez, R., Das, S., Kazer, S. W., Howard, N. C., Singh, A., et al. (2019) Nature 570:528–32. doi: 10.1038/s41586-019-1276-2

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is a leading cause of mortality, surpassing any other single infectious disease. Two billion people are infected with Mtb worldwide with 1.7 million deaths each year (1). One of the most critical factors leading to the global epidemic of TB is lack of adequate and safe vaccines. Although the current only licensed TB vaccine, Bacille Calmette-Guérin (BCG), can prevent Mtb infection in infants and young children, it can only provide partial and inconsistent protection (0–70%) to populations (1, 2). Most studies showed that BCG vaccination protection against tuberculosis lasts for up to 10 years, waning with time (3). Moreover, mounting explosion of drug-resistant TB and TB/HIV co-infection poses a serious threat to treatment and further prevention of the diseases (4, 5). Over the past decade, a worldwide collaborative effort to develop a novel preventive and/or therapeutic TB vaccine is unfortunately disappointing. Although some encouraging progress has been made, developing a vaccine more effective than BCG, and a new therapeutic strategy for treatment, remains an ongoing challenge, especially due to lack of crucial biomarkers and poor understanding of the mechanistic processes involving innate and adaptive immunity in the protection against this disease (4, 6).

Innate immunity against TB is very crucial in the control of early Mtb infection especially by pulmonary immune responses, which is mainly carried out by alveolar innate immune cells, such as macrophages, dendritic cells, monocytes, and neutrophils. Adaptive immunity against TB is also executed by Th1 and Th17 cells with TNF-α, IFN-γ, IL-17, and IL-22. Both IL-17 and IL-22 can recruit neutrophils, and activate macrophages, IFN-γ-producing CD8+ T cells, γδ T cells with perforin and granulysin as well as other T lymphocytes, including NKT and CD1-restricted αβ T cells (7, 8). Additionally, B cells in Mtb-infected lungs are also able to combat Mtb especially through generation of specific or nonspecific antibodies in a T cell-dependent or independent manner. They present Mtb antigens to Th cells, such as Th1, Th17, and Th7 cells. The latter release IFN-α and IFN-β to function, facilitate neutrophil migration via regulating Th17 cells to produce IL-17, and polarize lung macrophages (9).
Recently, a ground-breaking study on group 3 innate lymphoid cells (ILC3s) was reported in *Nature* (10). Ardain et al. (10) reveal for the first time that ILC3s mediate an early protective role in immunity to *Mtb* infection in lungs through generation of IL-17 and IL-22 in a C-X-C motif chemokine ligand 13 (CXCL13)–C-X-C motif chemokine receptor 5 (CXCR5)-dependent manner with formation of inducible bronchus-associated lymphoid tissue (iBALT) structures, providing a novel insight into the mechanistic process of interaction between TB infection and innate immune cells (Figure 1).

Recognized only in the past decade, ILCs have been currently classified into group 1 innate lymphoid cells (ILC1s), natural killer (NK) cells, group 2 innate lymphoid cells (ILC2s), ILC3s, lymphoid-tissue-inducer (LTi) cells, and regulatory innate lymphoid cells (ILCregs) on the basis of their development, phenotype, and function (11–13). ILC1s mainly produce the Th1-type cytokine IFN-γ. ILC2s secrete Th2-type cytokines, such as interleukin (IL)-4, IL-5, IL-9, and IL-13. ILC3s, including natural cytotoxicity receptor-negative (NCR−) and NCR+ ILC3s, primarily produce IL-17 and IL-22, like Th17 and Th22 cells. NK cells functionally represent the counterpart of the CD8+ cytotoxic T cells. Finally, ILCregs release both IL-10 and TGF-β to mirror the functions of Tregs (11, 14, 15). It is well-known that ILC3s exist mainly in intestinal mucosa, epithelial tissue, and skin, which are considered to function in tissue repair and mucosal homeostasis, whereas ILC2s are largely located in lung, skin, adipose tissue, and peripheral lymphatic tissues, which enable these tissues and organs to defend against helminth infection and allergen invasion.

The involvement of ILC3s in respiratory diseases is, to date, less well-defined. Inspiringly, Ardain et al. findings, that ILC3s but not ILC2s can protect lung tissue from *Mtb* early infection, make us regain recognition of novel actions of ILC3s in lungs. Importantly, they can initiate not only a rapid, non-specific response to extracellular microbes, but also a protection against intracellular specific pathogen *Mtb*, which is regarded as a crucial regulator in tissue homeostasis and inflammatory response (12).

In this study, the researchers observed that the population of ILCs, including the ILC3s, was highly exhausted in *Mtb*-infected patients compared to healthy individuals. Intriguingly, the number of ILC1s and ILC3s, but not ILC2s, restored upon treatment, indicating that *Mtb* bacteremia can modulate the accumulation of ILCs. Using human and mouse models of *Mtb* infection, they found that the accumulation of ILC3s synchronizes with alveolar macrophages increased in the lungs to reinforce *Mtb* control. The authors also tracked the localization of ILCs in several animal models and discovered that in the mice with intact immune system ILC3s migrate from the blood to the lung, homing to infected lung tissue, and produce messenger molecules IL-17 and IL-22. These cytokines are critical inducers of CXCL13 to recruit immune cells to form iBALT-associated granuloma structures in a CXCL13-CXCR5-dependent manner.

**FIGURE 1** | Regulatory role of ILC3s in early pulmonary tuberculosis. ILC3s move from blood to lung, and recruit immune cells through the IL-17 and IL-22 to form iBALT structures in a CXCL13-CXCR5-dependent manner, exerting an early protective effect on *Mtb* infection. DC, dendritic cells; FDC, follicular dendritic cells; HEV, high endothelial venules; iBALT, inducible bronchus-associated lymphoid tissues.
of the CXCL13-CXCR5 axis might be involved in the regulation of each ILC3 subpopulation in TB infection. Noteworthily, in the lungs of immunodeficient mice without functional ILC3s the number of macrophages was decreased with the poor immune control of TB, which demonstrates that macrophages can mediate especially activation of ILC3s through IL-1β.

On the other hand, intestinal CD103+CD11b+ DCs instruct the lung-specific trafficking of circulating IL-22+ ILC3s via boosting the lung-homing receptor CCR4 expression on IL-22+ ILC3s. The CCR4 is recruited by chemokine CCL17 or CCL20 generated by pulmonary epithelium cells (20). Ly6ClowCD11b+ activated monocytes increases the frequency of IL-17+ ILC3s in the lungs of K. pneumoniae-infected mice via producing TNF-α that markedly up-regulates the level of CCL20 in the lung epithelial cells (21). It is well-known that NCR− ILC3s primarily express IL-22, but NCR+ ILC3s predominantly produce IL-17 (12). Consequently, it deserves to be investigated how NCR− ILC3s home to the lungs, and whether pulmonary CD103+CD11b+ DCs function in lung-selective migration of NCR+ ILC3s.

Above all, ILC3s play a pivotal and previously underappreciated role in pulmonary TB immunity. They mainly mediate body’s early defense against TB infection through the IL-17/IL-22 axis in a CXCL13-CXCR5-dependent manner with formation of iBALT, which bridges a gap between innate immune cells and adaptive immune responses and advances our understanding of pathogenesis of TB. During Mtb infection, stromal cells, FDCs, and B cells express CXCL13 in iBALT, by which circulating CXCR5-expressing ILC3s are attracted into the lungs to mediate protective immunity from Mtb (18). The breakthrough discovery not only opens a door to research on ILCs for their regulating TB infection, but also paves a way to develop a potential treatment regimen for TB or especially drug-resistant TB. We reasonably infer that this early protective effect of ILC3s would appear in intestinal Mtb infection. However, how to target ILC3s or their secreted functional molecules, which contributes to the body to resist Mtb invasion, needs further exploration. Besides, BCG vaccination in animals unexpectedly initiates a rapidly strong recruitment of ILC3s that confer a protective immune response to Mtb in the lungs via the intranasal route administration, suggesting that there exist lung memory-like ILC3s (22). Hence, ILC3s play an important part in protective immunity against TB beyond our current recognition. We imagine that the memory-like ILC3s might be developed as potential vaccines in the future.

AUTHOR CONTRIBUTIONS

FX conceived of this commentary. BZ and FX drafted it. CD was responsible for the critical reading. FX and RX revised and finalized the manuscript. All the authors read and approved the final manuscript.

FUNDING

This work was supported by the National Natural Science Foundation of China (grant number 81172824) and Guangzhou City Science and Technology Program Synergistic Innovation Major Project (grant number 201604020146) to FX.

REFERENCES

1. Darrah PA, Zeppa JJ, Maiello P, Hackney JA, Wadsworth MHN, Hughes TK, et al. Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature. (2020) 577:95–102. doi: 10.1038/s41586-019-1817-8

2. Gupta N, Kumar R, Agrawal B. New players in immunity to tuberculosis: the host microbiome, lung epithelium, and innate immune cells. Front Immunol. (2018) 9:709. doi: 10.3389/fimmu.2018.00709

3. Abubakar I, Pimpin L, Artili C, Beynon R, Mangianti P, Sterne JA, et al. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guerin vaccination against tuberculosis. Health Technol Assess. (2013) 17:1–372. doi: 10.3310/hta17370

4. Hunter R, Actor J. The pathogenesis of post-primary tuberculosis. A game changer for vaccine development. Tuberculosis (Edinb). (2019) 116:5114–17. doi: 10.1016/j.tube.2019.04.018

5. Dheda K, Limberis JD, Pietersen E, Phelan J, Esmail A, Lessosky M, et al. Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmedatically incurable tuberculosis: a prospective cohort study. Lancet Respir Med. (2017) 5:269–81. doi: 10.1016/S2213-2600(16)00433-7

6. Ernst JD. Mechanisms of M. tuberculosis immune evasion as challenges to TB vaccine design. Cell Host Microbe. (2018) 24:34–42. doi: 10.1016/j.chom.2018.06.004

7. Etna MP, Giacomini E, Severa M, Coccia EM. Pro- and anti-inflammatory cytokines in tuberculosis: a two-edged sword in TB pathogenesis. Semin Immunol. (2014) 26:543–51. doi: 10.1016/j.smim.2014.09.011

8. Simmons JD, Stein CM, Seshadri C, Campo M, Alter G, Fortune S, et al. Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection. Nat Rev Immunol. (2018) 18:575–89. doi: 10.1038/s41577-018-0025-3

9. Dyallov AV, Apt AS, Linge IA. B lymphocytes in anti-mycobacterial immune responses: pathogenesis or protection? Tuberculosis. (2019) 114:1–8. doi: 10.1016/j.tube.2018.10.011
10. Ardain A, Domingo-Gonzalez R, Das S, Kazer SW, Howard NC, Singh A, et al. Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis. *Nature.* (2019) 570:528–32. doi: 10.1038/s41586-019-1276-2

11. Zeng B, Shi S, Liu J, Xing F. Commentary: regulatory innate lymphoid cells control innate intestinal inflammation. *Front Immunol.* (2018) 9:1522. doi: 10.3389/fimmu.2018.01522

12. Zeng BN, Shi SN, Ashworth G, Dong CJ, Liu J, Xing FY. ILC3 function as a double-edged sword in inflammatory bowel diseases. *Cell Death Dis.* (2019) 10:315. doi: 10.1038/s41419-019-1540-2

13. Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate lymphoid cells: 10 years on. *Cell.* (2018) 174:1054–66. doi: 10.1016/j.cell.2018.07.017

14. Colonna M. Innate lymphoid cells: diversity, plasticity, and unique functions in immunity. *Immunity.* (2018) 48:1104–17. doi: 10.1016/j.immuni.2018.05.013

15. Zook EC, Kee BL. Development of innate lymphoid cells. *Nat Immunol.* (2016) 17:775–82. doi: 10.1038/ni.3481

16. Ardain A, Porterfield JZ, Kloverpris HN, Leslie A. Type 3 ILCs in lung disease. *Front Immunol.* (2019) 10:92. doi: 10.3389/fimmu.2019.00092

17. Slight SR, Rangel-Moreno J, Gopal R, Lin Y, Fallert Junecko BA, Mehra S, et al. CXCR5(+) T helper cells mediate protective immunity against tuberculosis. *J Clin Invest.* (2013) 123:712–26. doi: 10.1172/JCI65728

18. Hwang JY, Randall TD, Silva-Sanchez A. Inducible bronchus-associated lymphoid tissue: taming inflammation in the lung. *Front Immunol.* (2016) 7:258. doi: 10.3389/fimmu.2016.00258

19. Hirahara K, Shinoda K, Morimoto Y, Kiuchi M, Aoki A, Kumagai J, et al. Immune cell-epithelial/mesenchymal interaction contributing to allergic airway inflammation associated pathology. *Front Immunol.* (2019) 10:570. doi: 10.3389/fimmu.2019.00570

20. Gray J, Oehle K, Worthy G, Alenghat T, Whitsett J, Deshmukh H. Intestinal commensal bacteria mediate lung mucosal immunity and promote resistance of newborn mice to infection. *Sci Transl Med.* (2017) 9:eaa9412. doi: 10.1126/scitranslmed.aaf9412

21. Xiong H, Keith JW, Samilo DW, Carter RA, Leiner IM, Pamer EG. Innate lymphocyte/Ly6C(+) monocyte crosstalk promotes klebsiella pneumoniae clearance. *Cell.* (2016) 165:679–89. doi: 10.1016/j.cell.2016.03.017

22. Choreno-Parra JA, Weinstein LI, Yunis EJ, Zuniga J, Hernandez-Pando R. Thinking outside the box: innate- and B cell-memory responses as novel protective mechanisms against tuberculosis. *Front Immunol.* (2020) 11:226. doi: 10.3389/fimmu.2020.00226

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Zeng, Xing, Dong and Xing. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.